InDex Pharmaceuticals Q2 2023: USD50m deal with Viatris - Redeye

Redeye believes Q2 was quite eventful for InDex Pharmaceuticals, with the highlight being a USD50m deal struck with Viatris. We have made some minor adjustments to our forecasts while still maintaining the view that InDex remains valued below fair value. To put things in perspective, the current market capitalization is roughly equivalent to the cash position.

Länk till analysen i sin helhet: https://www.redeye.se/research/937326/index-pharmaceuticals-q2-2023-usd50m-deal-with-viatris?utm_source=finwire&utm_medium=RSS